Institute of Health Economics and Health Care Management, Helmholtz Zentrum München (GmbH)-German Research Center for Environmental Health (GmbH), Neuherberg, Germany
German Center for Diabetes Research (DZD), München-Neuherberg, Germany.
Diabetes Care. 2018 May;41(5):971-978. doi: 10.2337/dc17-1763. Epub 2018 Jan 18.
The aim of this study is to provide reliable regression-based estimates of costs associated with different type 2 diabetes complications.
We used nationwide statutory health insurance (SHI) data from 316,220 patients with type 2 diabetes. Costs for inpatient and outpatient care, pharmaceuticals, rehabilitation, and nonmedical aids and appliances were assessed in the years 2013-2015. Quarterly observations are available for each year. We estimated costs (in 2015 euro) for complications using a generalized estimating equations model with a normal distribution adjusted for age, sex, occurrence of different complications, and history of complications at baseline, 2012. Two- and threefold interactions were included in an extended model.
The base case model estimated total costs in the quarter of event for the example of a 60- to 69-year-old man as follows: diabetic foot €1,293, amputation €14,284, retinopathy €671, blindness €2,933, nephropathy €3,353, end-stage renal disease (ESRD) €22,691, nonfatal stroke €9,769, fatal stroke €11,176, nonfatal myocardial infarction (MI)/cardiac arrest (CA) €8,035, fatal MI/CA €8,700, nonfatal ischemic heart disease (IHD) €6,548, fatal IHD €20,942, chronic heart failure €3,912, and angina pectoris €2,695. In the subsequent quarters, costs ranged from €681 for retinopathy to €6,130 for ESRD.
Type 2 diabetes complications have a significant impact on total health care costs in the SHI system, not only in the quarter of event but also in subsequent years. Men and women from different age-groups differ in their costs for complications. Our comprehensive estimates may support the parametrization of diabetes models and help clinicians and policy makers to quantify the economic burden of diabetes complications in the context of new prevention and treatment programs.
本研究旨在提供与 2 型糖尿病不同并发症相关的成本的可靠回归估计。
我们使用了来自 316220 名 2 型糖尿病患者的全国性法定健康保险(SHI)数据。评估了 2013 年至 2015 年期间住院和门诊护理、药品、康复以及非医疗辅助器具和设备的费用。每年都有季度观察数据。我们使用广义估计方程模型,根据年龄、性别、不同并发症的发生情况以及基线时并发症的历史,对 2012 年进行了正态分布调整,对每种并发症的成本(以 2015 年欧元计)进行了估计。在扩展模型中包括了二倍和三倍的交互作用。
基础模型估计了 60-69 岁男性患者在事件发生季度的总费用,具体如下:糖尿病足 €1293、截肢 €14284、视网膜病变 €671、失明 €2933、肾病 €3353、终末期肾病(ESRD) €22691、非致命性中风 €9769、致命性中风 €11176、非致命性心肌梗死(MI)/心脏骤停(CA) €8035、致命性 MI/CA €8700、非致命性缺血性心脏病(IHD) €6548、致命性 IHD €20942、慢性心力衰竭 €3912 和心绞痛 €2695。在随后的几个季度中,费用范围从视网膜病变的 €681 到 ESRD 的 €6130。
2 型糖尿病并发症不仅在事件发生的季度,而且在随后的几年中,对 SHI 系统的总医疗保健费用都有重大影响。不同年龄组的男性和女性在并发症的费用方面存在差异。我们的综合估计可能有助于糖尿病模型的参数化,并帮助临床医生和决策者在新的预防和治疗方案背景下量化糖尿病并发症的经济负担。